Once a new therapeutic agent or strategy has been thoroughly studied in preclinical studies, the information generated typically is submitted to the Food and Drug Administration (FDA) as part of an Investigational New Drug (IND) application. Evaluation of the therapeutic agent or strategy in human subjects can begin once FDA has approved the IND application.
Clinical trials commonly are designed to investigate the safety and efficacy of new therapeutic agents for the treatment of HIV and its co-infections. The consequences of residual inflammation in virally suppressed individuals are also under investigation. The underlying pathogenic mechanisms are unknown or poorly understood. The potential for HIV eradication or long term remission in the absence of HAART are also areas of intense research. NIAID’s current research activities include the following:
Last Updated July 23, 2015